Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 380

Sort by

Sort Order Select

Journal Articles

Predicting the future for DLBCL

Bruce D. Cheson

Blood (2020) 135 (16): 1308–1309.

https://doi.org/10.1182/blood.2020005002

Published: 2020

Journal Articles

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Blood (2020) 135 (16): 1396–1405.

https://doi.org/10.1182/blood.2019003526

Published: 2020

Includes: Supplemental data

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Leandro Cerchietti, MD, Giorgio Inghirami, MD, Nikita Kotlov, PhD, Viktor Svekolkin, PhD, Alexander Bagaev, PhD, Felix Frenkel, PhD, Maria Victoria Revuelta, PhD, Jude M Phillip, PhD, Maria Teresa Cacciapuoti, MS, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, John P. Leonard, MD

Blood (2019) 134 (Supplement_1): 656.

https://doi.org/10.1182/blood-2019-128889

Published: 2019

Journal Articles

Myeloma Derived Extracellular Vesicles Containing Endoplasmic Reticulum Remodel the Bone Marrow Microenvironment Towards a Pro-Tumoral Senescent Phenotype

Yu Sun, BSc, MSc, PhD, Jayna J Mistry, BSc, Jamie A Moore, BSc, MSc, Charlotte Hellmich, MBBChir, Christopher R Marlein, PhD, Anna Haestier, Cesar A. Gomez, MD PhD FRCPath, Christopher J Morris, PhD, Kristian M Bowles, MBBS, PhD, Stuart A Rushworth, PhD

Blood (2019) 134 (Supplement_1): 689.

https://doi.org/10.1182/blood-2019-128268

Published: 2019

Journal Articles

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Giada Bianchi, MD, Peter G. Czarnecki, MD, Matthew Ho, PhD, Aldo M. Roccaro, MD PhD, Antonio Sacco, RN, Yawara Kawano, MD PhD, Anil Aktas Samur, PhD, Annamaria Gulla, MD, Tianzeng Chen, Kenneth Wen, Xinchen Wu, Yu-Tzu Tai, PhD, Gulden Camci-Unal, PhD, Irene M. Ghobrial, MD, Ruben D. Carrasco, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 507.

https://doi.org/10.1182/blood-2019-128778

Published: 2019

Journal Articles

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Akinori Yoda, PhD, Daisuke Morishita, PhD, Akio Mizutani, PhD, Yoshihiko Satoh, PhD, Yotaro Ochi, MD, Yasuhito Nannya, MD PhD, Hideki Makishima, MD PhD, Hiroshi Miyake, PhD, Seishi Ogawa, MD PhD

Blood (2019) 134 (Supplement_1): 404.

https://doi.org/10.1182/blood-2019-131559

Published: 2019

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Toshiki Terao, MD, Yoichi Machida, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1861.

https://doi.org/10.1182/blood-2019-130845

Published: 2019

Journal Articles

Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All- Trans retinoic Acid (ATRA) through the Transcription Factor CREB

Blood (2019) 134 (Supplement_1): 1692.

https://doi.org/10.1182/blood-2019-128573

Published: 2019

Journal Articles

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Lilly Wong, Rama Krishna Narla, Jim Leisten, Daniel Bauer, Matthew Groza, Bonny Gaffney, Courtney G. Havens, Justin Choi, Jack Houston, Antonia Lopez-Girona, Joshua Hansen, Brian E. Cathers, James Carmichael, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 1815.

https://doi.org/10.1182/blood-2019-124345

Published: 2019

Journal Articles

Exploring the Potential of Shallow Whole-Genome Sequencing for Diagnosis and Disease Monitoring of Lymphoma in Liquid Biopsy

Lennart Raman, MSc, Malaïka Van Der Linden, MSc, Ciel De Vriendt, Bliede Van Den Broeck, MD, Kristoff Muylle, MD, Dries Deeren, MD PhD, Bjorn Menten, PhD, Fritz Offner, MD, Jo Van Dorpe, MD PhD

Blood (2019) 134 (Supplement_1): 2087.

https://doi.org/10.1182/blood-2019-131391

Published: 2019

Journal Articles

Clinical Significance of Uptake Value on F18-FDG PET/CT and Histological Grade in 164 Patients with Follicular Lymphoma Including Transformation - a Single Center Retrospective Study

Mitsuhiro Yuasa, MD, Daisuke Kaji, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD

Blood (2019) 134 (Supplement_1): 1529.

https://doi.org/10.1182/blood-2019-130837

Published: 2019

Journal Articles

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Heiko Schoder, MD, Jisun Lee, Theresa Davey, MMSc, PA-C, Helen Hancock, ANP, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, M. Lia Palomba, MD, Gunjan L. Shah, MDMS, Miguel-Angel Perales, MD, Craig S. Sauter, MD, David J. Straus, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 1555.

https://doi.org/10.1182/blood-2019-129364

Published: 2019

Journal Articles

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Vinitha Mary Kuruvilla, MSc, Rebecca McCarthy, Qi Zhang, PhD, Callum M. Sloss, PhD, Patrick A. Zweidler-McKay, MD PhD, Angela Romanelli, PhD, Sharlene Adams, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1375.

https://doi.org/10.1182/blood-2019-124963

Published: 2019

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Journal Articles

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

Anna Bunin, PhD, Katy McGrath, BS, Ann Marie Rossi, MS, Matthew Welsch, PhD, Christian Vidal, PhD, David Trinh, BA, David Spiegel, MD, PhD, Luca Rastelli, PhD, Enrique Alvarez, DVM

Blood (2019) 134 (Supplement_1): 1820.

https://doi.org/10.1182/blood-2019-130838

Published: 2019

Journal Articles

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Akihiro Kitadate, MD PhD, Kentaro Narita, MD, Kota Fukumoto, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Youichi Machida, MD, Naoto Takahashi, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 2839.

https://doi.org/10.1182/blood-2019-122799

Published: 2019

NARROW

Predicting the future for DLBCL

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Myeloma Derived Extracellular Vesicles Containing Endoplasmic Reticulum Remodel the Bone Marrow Microenvironment Towards a Pro-Tumoral Senescent Phenotype

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All- Trans retinoic Acid (ATRA) through the Transcription Factor CREB

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Exploring the Potential of Shallow Whole-Genome Sequencing for Diagnosis and Disease Monitoring of Lymphoma in Liquid Biopsy

Clinical Significance of Uptake Value on F18-FDG PET/CT and Histological Grade in 164 Patients with Follicular Lymphoma Including Transformation - a Single Center Retrospective Study

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only